Argenx falls as Sjögren’s setback offsets celiac drug progress

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 08 Oct, 15:38 UTC

A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ‘blockbuster expansion opportunity’ for Vyvgart.

science

Sources

• T2Argenx falls as Sjögren’s setback offsets celiac drug progressBioPharma Dive / Healthcare Dive / MedTech Dive08 Oct, 15:38